MedPath

Glyburide

Generic Name
Glyburide
Brand Names
Diabeta, Glucovance, Glynase, Amglidia
Drug Type
Small Molecule
Chemical Formula
C23H28ClN3O5S
CAS Number
10238-21-8
Unique Ingredient Identifier
SX6K58TVWC
Background

Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. It is typically given to patients who cannot be managed with the standard first line therapy, metformin. Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and calcium ion concentrations.

Glyburide was granted FDA approval on 1 May 1984. A formulation with metformin was granted FDA approval on on 31 July 2000.

Indication

Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.

Associated Conditions
Gestational Diabetes Mellitus (GDM), Glycemic Control, Type 2 Diabetes Mellitus
Clinical Trials
Related News

Comparison Between Metformin and Glyburide in the Management of Gestational Diabetes

Not Applicable
Not yet recruiting
Conditions
Gestational Diabetes Mellitus in Pregnancy
Interventions
First Posted Date
2024-09-10
Last Posted Date
2024-09-10
Lead Sponsor
Assiut University
Target Recruit Count
180
Registration Number
NCT06589141

Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients

Phase 3
Not yet recruiting
Conditions
Diabetes Mellitus Type 2 Without Complication
Interventions
First Posted Date
2023-01-18
Last Posted Date
2023-07-03
Lead Sponsor
University of Zambia
Target Recruit Count
118
Registration Number
NCT05688332

Oral Glibenclamide in Preterm Infants with Hyperglycaemia (GALOP)

Phase 2
Recruiting
Conditions
Transient; Hypoglycemia, Neonatal
Preterm
Glibenclamide Adverse Reaction
Interventions
Biological: Pharmacokinetics study
Biological: C-peptide proinsulin ratio
Biological: Blood glucose on fluorinated tube
Biological: Routine biological monitoring
Biological: glycose holter monitor
First Posted Date
2023-01-18
Last Posted Date
2025-01-20
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
45
Registration Number
NCT05687500
Locations
🇫🇷

Hopital Necker - Enfants malades, Paris, France

Spinal Cord Injury Neuroprotection With Glyburide

Phase 1
Recruiting
Conditions
Acute Spinal Cord Injury
Interventions
First Posted Date
2022-06-22
Last Posted Date
2024-10-11
Lead Sponsor
University of Kentucky
Target Recruit Count
12
Registration Number
NCT05426681
Locations
🇺🇸

University of Kentucky, Lexington, Kentucky, United States

To Evaluate the Effect of Glibenclamide in Reducing Brain Edema of TBI

Phase 1
Conditions
Traumatic Brain Injury
Interventions
First Posted Date
2021-12-08
Last Posted Date
2021-12-08
Lead Sponsor
Beijing Tiantan Hospital
Target Recruit Count
76
Registration Number
NCT05148403
Locations
🇨🇳

Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, Beijing, China

🇨🇳

Beijing Tongren Hospital, Capital Medical University, Beijing, China

Evaluate the Use of Glibenclamide on Acute aSAH

Phase 4
Conditions
Subarachnoid Hemorrhage
Interventions
First Posted Date
2021-11-30
Last Posted Date
2022-02-14
Lead Sponsor
Beijing Tiantan Hospital
Target Recruit Count
110
Registration Number
NCT05137678
Locations
🇨🇳

Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, Beijing, China

The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers

Not Applicable
Completed
Conditions
Pain
Headache
Migraine
Interventions
First Posted Date
2021-07-14
Last Posted Date
2021-07-14
Lead Sponsor
Danish Headache Center
Target Recruit Count
22
Registration Number
NCT04960657
Locations
🇩🇰

Danish Headache Center, Copenhagen, Capital Region, Denmark

A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: DBPR108 tablets
First Posted Date
2021-04-26
Last Posted Date
2021-07-20
Lead Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Target Recruit Count
56
Registration Number
NCT04859452
Locations
🇨🇳

First Affiliated Hospital of Soochow University, Suzhou, China

The Hemodynamic Effects of CGRP After Glibenclamide Administration in Healthy Volunteers

Not Applicable
Completed
Conditions
Hemodynamics of Cranial Arteries
Headache
Cerebral Blood Flow
Interventions
Drug: Placebo
First Posted Date
2020-01-18
Last Posted Date
2020-09-09
Lead Sponsor
Danish Headache Center
Target Recruit Count
20
Registration Number
NCT04231617
Locations
🇩🇰

Mohammad Al-Mahdi Al-Karagholi, København S, Danmark, Denmark

🇩🇰

Danish headache center, Glostrup, Copenhagen, Denmark

A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion

Phase 2
Terminated
Conditions
Brain Contusion
Interventions
Drug: Placebo
First Posted Date
2019-05-17
Last Posted Date
2024-11-27
Lead Sponsor
Remedy Pharmaceuticals, Inc.
Target Recruit Count
92
Registration Number
NCT03954041
Locations
🇺🇸

Grady Memorial Hospital, Atlanta, Georgia, United States

🇺🇸

Goodman Campbell Brain and Spine, Carmel, Indiana, United States

🇺🇸

University of Maryland Medical Center, Baltimore, Maryland, United States

and more 60 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy